Covid Study to Assess Pfizer, J&J Suitability for HIV Infected

Jan. 12, 2022, 8:30 AM

A South African Covid-19 vaccine trial will assess the safety and impact of varying doses of Johnson & Johnson and Pfizer Inc. shots as boosters for those infected with HIV as well as the wider population.

The study being carried out by the Johannesburg-based Wits Reproductive Health and HIV Institute will recruit about 300 health workers, of which about a third will be HIV positive, said Lee Fairlie,head of child and maternal health at the institute.

With about 8.2 million people in South Africa, or 13% of the population, infected with HIV, the effectiveness, or immunogenicity, of Covid-19 vaccines ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.